Gilead Sciences Inc (GILD)

81.47
0.55 0.68
NASDAQ : Health Care
Prev Close 80.92
Open 81.46
Day Low/High 81.02 / 81.64
52 Wk Low/High 77.92 / 113.31
Volume 8.27M
Avg Volume 10.21M
Exchange NASDAQ
Shares Outstanding 1.32B
Market Cap 106.89B
EPS 12.40
P/E Ratio 7.14
Div & Yield 1.88 (2.30%)

Latest News

European Commission Grants Marketing Authorization For Gilead's Once-Daily Truvada® For Reducing The Risk Of Sexually Acquired HIV-1

European Commission Grants Marketing Authorization For Gilead's Once-Daily Truvada® For Reducing The Risk Of Sexually Acquired HIV-1

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Truvada ® (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination...

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Gilead Sciences (GILD) Stock Up, Piper Jaffray: Splitting Is 'Poor Idea'

Gilead Sciences (GILD) Stock Up, Piper Jaffray: Splitting Is 'Poor Idea'

Analysts at Piper Jaffray said in a note this morning that Gilead Sciences (GILD) can create value without splitting its HIV and HCV franchises.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

S&P Isn't My Favorite Subject

A breakout is hard to come by.

Gilead (GILD) Stock Lower, Piper Jaffray: Little Required to 'Driver Shares Higher'

Gilead (GILD) Stock Lower, Piper Jaffray: Little Required to 'Driver Shares Higher'

Piper Jaffray analysts say Gilead Sciences (GILD) could be moving toward a 'modest' multiple.

Weekly Roundup: Why Current Valuations Make Little Sense

Big gainers last week, and a roundup of portfolio changes.

How Will Gilead (GILD) Stock React to Hepatitis-C Drug Prescriptions?

How Will Gilead (GILD) Stock React to Hepatitis-C Drug Prescriptions?

Prescription data for Gilead's (GILD) hepatitis-C treatments were mixed for the week ended August 5, according to Leerink.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

Trade Idea: Time to Get Long Gilead

We think this is a ridiculously cheap stock.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Gilead (GILD) Stock Slumps, Leerink: Drug Success Overshadowed By Sales Decline

Gilead (GILD) Stock Slumps, Leerink: Drug Success Overshadowed By Sales Decline

Leerink analysts said Gilead's (GILD) sales decline could be the result of several factors.

Watch Gilead for Buying Opportunities

Watch Gilead for Buying Opportunities

There is a case for a low already being in place.

CMCSA, IDXX, ZTS: Jim Cramer's Views

CMCSA, IDXX, ZTS: Jim Cramer's Views

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the health services industry higher today.

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Gilead Sciences Has No Cure in Sight for Increasing Competition

Gilead Sciences Has No Cure in Sight for Increasing Competition

In the last year, shares of Gilead Sciences are down 32%. With competition increasing for its hepatitis-C treatment, it is unlikely shareholders will see any relief.

The Good, Bad and Ugly; A Reason to Give Up POT: Best of Kass

The Good, Bad and Ugly; A Reason to Give Up POT: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about the good, the bad and the ugly.

Gilead (GILD) Stock Down on Q3 Outlook, Argus Downgrades

Gilead (GILD) Stock Down on Q3 Outlook, Argus Downgrades

Gilead (GILD) stock was downgraded to ‘hold’ at Argus this morning.

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

The company's hepatitis C drug division is expected to see losses in the second half of the year.

5 Blue-Chip Breakouts to Buy This Summer

5 Blue-Chip Breakouts to Buy This Summer

Some of this month's most explosive moves are coming from large-cap stocks. Here's how to profit from five of them.